118096-36-9Relevant academic research and scientific papers
Regioselective Decarboxylative Cycloaddition Route to Fully Substituted 3-CF3-Pyrazoles from Nitrilimines and Isoxazolidinediones
Tian, Yu-Chen,Li, Jun-Kuan,Zhang, Fa-Guang,Ma, Jun-An
supporting information, p. 2093 - 2097 (2021/03/15)
1,4-Diaryl-5-carboxamido substituted 3-trifluoromethylpyrazoles are obtained with exclusive regioselectivity under transition-metal-free conditions. This decarboxylative [3+2] cycloaddition protocol was enabled by employing trifluoromethyl nitrilimines as 1,3-dipoles, and isoxazolidinediones as CO2-masked alkynyl dipolarophiles. The applicability of this method is further manifested by its compatibility with difluoromethyl, alkyl, aryl, and heteroaryl nitrilimines, as well as the preparation of 4-carboxylic amido analogue of drug Celebrex. (Figure presented.).
Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists
Shi, Jun,Gu, Zhengxiang,Jurica, Elizabeth Anne,Wu, Ximao,Haque, Lauren E.,Williams, Kristin N.,Hernandez, Andres S.,Hong, Zhenqiu,Gao, Qi,Dabros, Marta,Davulcu, Akin H.,Mathur, Arvind,Rampulla, Richard A.,Gupta, Arun Kumar,Jayaram, Ramya,Apedo, Atsu,Moore, Douglas B.,Liu, Heng,Kunselman, Lori K.,Brady, Edward J.,Wilkes, Jason J.,Zinker, Bradley A.,Cai, Hong,Shu, Yue-Zhong,Sun, Qin,Dierks, Elizabeth A.,Foster, Kimberly A.,Xu, Carrie,Wang, Tao,Panemangalore, Reshma,Cvijic, Mary Ellen,Xie, Chunshan,Cao, Gary G.,Zhou, Min,Krupinski, John,Whaley, Jean M.,Robl, Jeffrey A.,Ewing, William R.,Ellsworth, Bruce Alan
, p. 681 - 694 (2018/02/16)
G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly selective and potent GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion. Employing strategies to increase polarity and the ratio of sp3/sp2 character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.
Dihydropyrazole GPR40 modulators
-
Page/Page column 46; 47, (2015/10/05)
The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
DIHYDROPYRAZOLE GPR40 MODULATORS
-
, (2014/06/11)
The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
